Free Trial

Harrow Q2 2024 Earnings Report

Harrow logo
$36.10 +2.25 (+6.65%)
As of 01/21/2025 04:00 PM Eastern

Harrow EPS Results

Actual EPS
-$0.13
Consensus EPS
-$0.25
Beat/Miss
Beat by +$0.12
One Year Ago EPS
N/A

Harrow Revenue Results

Actual Revenue
$48.94 million
Expected Revenue
$42.78 million
Beat/Miss
Beat by +$6.16 million
YoY Revenue Growth
N/A

Harrow Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Harrow Earnings Headlines

Harrow announces Amir Shojaei, PharmD, PhD joins as CSO
Harrow Health (HROW) Gets a Buy from Craig-Hallum
Trump currency shock imminent
Trump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launched a $1.9 trillion move against the Fed. What comes next could have dramatic consequences.
Those Derisked Baby Bonds Of Harrow, Inc.
See More Harrow Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Harrow? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Harrow and other key companies, straight to your email.

About Harrow

Harrow (NASDAQ:HROW) operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

View Harrow Profile

More Earnings Resources from MarketBeat